ERBB2 and breast cancer: Similar to the immune checkpoint inhibition-based mathematical model given in [145], quantitative information about the association of PD-L1 expression, Tregs, and TILs in the tumor microenvironment can predict whether a HER2+ BC patient will benefit from immune checkpoint inhibition [115,127].